Astragaloside IV (BioDeep_00000000147)

 

Secondary id: BioDeep_00000171753, BioDeep_00000329969

PANOMIX_OTCML-2023 natural product


代谢物信息卡片


(2R,3R,4S,5S,6R)-2-(((2aR,3R,4S,5aS,5bS,7S,7aR,9S,11aR,12aS)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

化学式: C41H68O14 (784.4609)
中文名称: 黄芪皂苷 IV, 黄芪甲苷, 黄芪甙, 黄芪甲苷A(黄芪甲苷 IV)
谱图信息: 最多检出来源 Chinese Herbal Medicine(otcml) 60.47%

Reviewed

Last reviewed on 2024-08-08.

Cite this Page

Astragaloside IV. BioDeep Database v3. PANOMIX ltd, a top metabolomics service provider from China. https://query.biodeep.cn/s/astragaloside_iv (retrieved 2024-12-22) (BioDeep RN: BioDeep_00000000147). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

分子结构信息

SMILES: CC(C)(O)C1CCC(C)(C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C5C(C)(C)C(OC6OCC(O)C(O)C6O)CCC56CC46CCC23C)O1
InChI: InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3

描述信息

Astragaloside IV is a pentacyclic triterpenoid that is cycloastragenol having beta-D-xylopyranosyl and beta-D-glucopyranosyl residues attached at positions O-3 and O-6 respectively. It is isolated from Astragalus membranaceus var mongholicus. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor, an anti-inflammatory agent, a neuroprotective agent, an antioxidant, a pro-angiogenic agent and a plant metabolite. It is a triterpenoid saponin and a pentacyclic triterpenoid. It is functionally related to a cycloastragenol.
Astragaloside IV is a natural product found in Euphorbia glareosa, Astragalus ernestii, and other organisms with data available.
A pentacyclic triterpenoid that is cycloastragenol having beta-D-xylopyranosyl and beta-D-glucopyranosyl residues attached at positions O-3 and O-6 respectively. It is isolated from Astragalus membranaceus var mongholicus.
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

同义名列表

29 个代谢物同义名

(2R,3R,4S,5S,6R)-2-(((2aR,3R,4S,5aS,5bS,7S,7aR,9S,11aR,12aS)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; (2R,3R,4S,5S,6R)-2-[[(1S,3R,8R,9S,11S,12S,14S,15R,16R)-14-Hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; .BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,6.ALPHA.,16.BETA.,20R,24S)-20,24-EPOXY-16,25-DIHYDROXY-3-(.BETA.-D-XYLOPYRANOSYLOXY)-9,19-CYCLOLANOSTAN-6-YL; beta-D-Glucopyranoside, (3beta,6alpha,16beta,20R,24S)-20,24-epoxy-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl; Astragaloside IV, United States Pharmacopeia (USP) Reference Standard; 3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosylcycloastragenol; Astragaloside IV, European Pharmacopoeia (EP) Reference Standard; 3beta,6alpha,16beta,20R,24S; astragaloside IV of astragaloside A; ASTRAGALOSIDE IV (CONSTITUENT OF ASTRAGALUS) [DSC]; Astramembrannin I;Astragalin A; ASTRAGALOSIDE IV [USP-RS]; Astragaloside IV, >98.0\\%; Astrasieversianin XIV; Astragaloside IV 95\\%; Cyclosieversioside F; cyclosiversioside F; ASTRAVERSIANIN XIV; astramembrannin I; Astragaloside IV; astragaloside A; AstragalosideIV; UNII-1J6XA9YCFV; astragaloside-A; Astragaloside; 1J6XA9YCFV; AST-IV; AS-IV; Astragaloside IV



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

41 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 15 ABCB1, ANG, CASP9, CDK4, CTNNB1, EGFR, MAPK14, NOS2, PPARG, PRKAA2, PTGS2, RB1, SMAD2, STAT3, TLR4
Peripheral membrane protein 1 PTGS2
Endosome membrane 2 EGFR, TLR4
Endoplasmic reticulum membrane 2 EGFR, PTGS2
Nucleus 13 ANG, CASP9, CDK4, CTNNB1, EGFR, MAPK14, NOS2, PPARG, PPARGC1A, PRKAA2, RB1, SMAD2, STAT3
cytosol 12 ANG, CASP9, CDK4, CTNNB1, MAPK14, NOS2, PPARG, PPARGC1A, PRKAA2, RB1, SMAD2, STAT3
dendrite 1 PRKAA2
centrosome 1 CTNNB1
nucleoplasm 10 CDK4, CTNNB1, MAPK14, NOS2, PPARG, PPARGC1A, PRKAA2, RB1, SMAD2, STAT3
RNA polymerase II transcription regulator complex 2 PPARG, STAT3
Cell membrane 5 ABCB1, CTNNB1, EGFR, PECAM1, TLR4
lamellipodium 1 CTNNB1
ruffle membrane 1 EGFR
Early endosome membrane 1 EGFR
Multi-pass membrane protein 1 ABCB1
Synapse 1 CTNNB1
cell cortex 1 CTNNB1
cell junction 3 CTNNB1, EGFR, PECAM1
cell surface 3 ABCB1, EGFR, TLR4
glutamatergic synapse 3 CTNNB1, EGFR, MAPK14
Golgi apparatus 1 PRKAA2
Golgi membrane 1 EGFR
growth cone 1 ANG
neuronal cell body 2 ANG, PRKAA2
presynaptic membrane 1 CTNNB1
Cytoplasm, cytosol 1 NOS2
endosome 1 EGFR
plasma membrane 7 ABCB1, CTNNB1, EGFR, NOS2, PECAM1, STAT3, TLR4
Membrane 6 ABCB1, CTNNB1, EGFR, PRKAA2, SMAD2, TLR4
apical plasma membrane 2 ABCB1, EGFR
axon 1 PRKAA2
basolateral plasma membrane 2 CTNNB1, EGFR
caveola 1 PTGS2
extracellular exosome 3 ABCB1, CTNNB1, PECAM1
endoplasmic reticulum 1 PTGS2
extracellular space 6 ANG, CCL2, CXCL8, EGFR, IL17A, PECAM1
perinuclear region of cytoplasm 5 CTNNB1, EGFR, NOS2, PPARG, TLR4
Schaffer collateral - CA1 synapse 1 CTNNB1
adherens junction 1 CTNNB1
apicolateral plasma membrane 1 CTNNB1
bicellular tight junction 2 CDK4, CTNNB1
mitochondrion 2 CASP9, MAPK14
protein-containing complex 6 CASP9, CTNNB1, EGFR, PECAM1, PTGS2, SMAD2
intracellular membrane-bounded organelle 1 PPARG
Microsome membrane 1 PTGS2
Single-pass type I membrane protein 3 EGFR, PECAM1, TLR4
Secreted 4 ANG, CCL2, CXCL8, IL17A
extracellular region 5 ANG, CCL2, CXCL8, IL17A, MAPK14
transcription regulator complex 4 CDK4, CTNNB1, SMAD2, STAT3
Nucleus membrane 1 CDK4
nuclear membrane 2 CDK4, EGFR
external side of plasma membrane 3 IL17A, PECAM1, TLR4
actin cytoskeleton 1 ANG
Z disc 1 CTNNB1
beta-catenin destruction complex 1 CTNNB1
nucleolus 2 ANG, CDK4
Wnt signalosome 1 CTNNB1
Cytoplasm, P-body 1 NOS2
P-body 1 NOS2
Early endosome 1 TLR4
apical part of cell 1 CTNNB1
cell-cell junction 2 CTNNB1, PECAM1
postsynaptic membrane 1 CTNNB1
Apical cell membrane 1 ABCB1
Cytoplasm, perinuclear region 1 NOS2
Membrane raft 2 EGFR, PECAM1
Cytoplasm, cytoskeleton 1 CTNNB1
focal adhesion 2 CTNNB1, EGFR
spindle 1 RB1
Cell junction, adherens junction 1 CTNNB1
flotillin complex 1 CTNNB1
Peroxisome 1 NOS2
basement membrane 1 ANG
intracellular vesicle 1 EGFR
peroxisomal matrix 1 NOS2
Nucleus, PML body 1 PPARGC1A
PML body 2 PPARGC1A, RB1
fascia adherens 1 CTNNB1
lateral plasma membrane 1 CTNNB1
nuclear speck 2 MAPK14, PRKAA2
Nucleus inner membrane 1 PTGS2
Nucleus outer membrane 1 PTGS2
nuclear inner membrane 1 PTGS2
nuclear outer membrane 1 PTGS2
Cell projection, ruffle 1 TLR4
ruffle 1 TLR4
receptor complex 3 EGFR, PPARG, TLR4
neuron projection 1 PTGS2
chromatin 6 CDK4, PPARG, PPARGC1A, RB1, SMAD2, STAT3
phagocytic cup 1 TLR4
cell periphery 1 CTNNB1
Chromosome 1 ANG
Cytoplasm, cytoskeleton, cilium basal body 1 CTNNB1
Nucleus, nucleolus 1 ANG
spindle pole 2 CTNNB1, MAPK14
postsynaptic density, intracellular component 1 CTNNB1
microvillus membrane 1 CTNNB1
Endomembrane system 1 CTNNB1
Cytoplasm, Stress granule 1 ANG
cytoplasmic stress granule 2 ANG, PRKAA2
euchromatin 1 CTNNB1
basal plasma membrane 1 EGFR
synaptic membrane 1 EGFR
lipopolysaccharide receptor complex 1 TLR4
ficolin-1-rich granule lumen 1 MAPK14
secretory granule lumen 1 MAPK14
secretory granule membrane 1 PECAM1
endoplasmic reticulum lumen 1 PTGS2
endocytic vesicle 1 ANG
beta-catenin-TCF complex 1 CTNNB1
SWI/SNF complex 1 RB1
apoptosome 1 CASP9
presynaptic active zone cytoplasmic component 1 CTNNB1
clathrin-coated endocytic vesicle membrane 1 EGFR
[Isoform 1]: Nucleus 1 PPARGC1A
heteromeric SMAD protein complex 1 SMAD2
SMAD protein complex 1 SMAD2
protein-DNA complex 1 CTNNB1
external side of apical plasma membrane 1 ABCB1
nucleotide-activated protein kinase complex 1 PRKAA2
[Isoform Long]: Cell membrane 1 PECAM1
catenin complex 1 CTNNB1
platelet alpha granule membrane 1 PECAM1
activin responsive factor complex 1 SMAD2
cyclin-dependent protein kinase holoenzyme complex 1 CDK4
multivesicular body, internal vesicle lumen 1 EGFR
Shc-EGFR complex 1 EGFR
cortical cytoskeleton 1 NOS2
angiogenin-PRI complex 1 ANG
chromatin lock complex 1 RB1
Rb-E2F complex 1 RB1
cyclin D1-CDK4 complex 1 CDK4
cyclin D2-CDK4 complex 1 CDK4
cyclin D3-CDK4 complex 1 CDK4
beta-catenin-TCF7L2 complex 1 CTNNB1
[Isoform Delta15]: Cell junction 1 PECAM1
beta-catenin-ICAT complex 1 CTNNB1
Scrib-APC-beta-catenin complex 1 CTNNB1
caspase complex 1 CASP9
homomeric SMAD protein complex 1 SMAD2
[Isoform B4]: Nucleus 1 PPARGC1A
[Isoform B4-8a]: Cytoplasm 1 PPARGC1A
[Isoform B5]: Nucleus 1 PPARGC1A
[Isoform 9]: Nucleus 1 PPARGC1A


文献列表

  • Jianan Guo, Yifei Le, Aini Yuan, Jing Liu, Hang Chen, Jiannan Qiu, Cui Wang, Xiaobing Dou, Xingyu Yuan, Dezhao Lu. Astragaloside IV ameliorates cisplatin-induced liver injury by modulating ferroptosis-dependent pathways. Journal of ethnopharmacology. 2024 Jun; 328(?):118080. doi: 10.1016/j.jep.2024.118080. [PMID: 38521426]
  • Junfeng Guo, Yuwei Zhang, Rui Zhou, Yanwei Hao, Xuanyu Wu, Ganggang Li, Quanyu Du. Deciphering the molecular mechanism of Bu Yang Huan Wu Decoction in interference with diabetic pulmonary fibrosis via regulating oxidative stress and lipid metabolism disorder. Journal of pharmaceutical and biomedical analysis. 2024 Jun; 243(?):116061. doi: 10.1016/j.jpba.2024.116061. [PMID: 38430615]
  • Qiu-Yue Wang, Shu-Yu Liu, Dong-Hua Yu, Ping-Ping Chen, Yu Wang, Fang Lu, Shu-Min Liu. Evaluation of drug interactions of Saposhnikoviae Radix and its major components with astragaloside IV and paeoniflorin using in vitro and in vivo experiments. Journal of chromatography. A. 2024 May; 1723(?):464716. doi: 10.1016/j.chroma.2024.464716. [PMID: 38640881]
  • Tian-Ci Zhang, Yi-Can Lin, Ning-Ning Sun, Shan Liu, Wen-Zhu Hu, Yan Zhao, Xian-Hui Dong, Xiao-Ping He. Icariin, astragaloside a and puerarin mixture attenuates cognitive impairment in APP/PS1 mice via inhibition of ferroptosis-lipid peroxidation. Neurochemistry international. 2024 May; 175(?):105705. doi: 10.1016/j.neuint.2024.105705. [PMID: 38412923]
  • Xinhui Zhang, Fan Zhang, Yan Li, Na Fan, Ke Zhao, Anding Zhang, Jiefang Kang, Yan Lin, Xiaochang Xue, Xun Jiang. Blockade of PI3K/AKT signaling pathway by Astragaloside IV attenuates ulcerative colitis via improving the intestinal epithelial barrier. Journal of translational medicine. 2024 Apr; 22(1):406. doi: 10.1186/s12967-024-05168-w. [PMID: 38689349]
  • Guo Liu, Ye-Hui Wang, Ting Zhang, Ya-Qiong Li, Xin-Yue Chen, Wei Dong, Wei Li, Qi-Xiang Miao, Wen-Bo Qiao, Hui-Qiang Tian, Shi-Long Yin. Astragaloside-IV promotes autophagy via the Akt/mTOR pathway to improve cellular lipid deposition. Medicine. 2024 Apr; 103(16):e37846. doi: 10.1097/md.0000000000037846. [PMID: 38640324]
  • Xujun You, Junfeng Qiu, Qixin Li, Qing Zhang, Wen Sheng, Yiguo Cao, Wei Fu. Astragaloside IV-PESV inhibits prostate cancer tumor growth by restoring gut microbiota and microbial metabolic homeostasis via the AGE-RAGE pathway. BMC cancer. 2024 Apr; 24(1):472. doi: 10.1186/s12885-024-12167-z. [PMID: 38622523]
  • Xiangyu Chen, Tong Yang, Yue Zhou, Zhigang Mei, Wenli Zhang. Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO/deSUMOylation in cerebral ischemia-reperfusion injury. CNS neuroscience & therapeutics. 2024 04; 30(4):e14725. doi: 10.1111/cns.14725. [PMID: 38615367]
  • Yanyun Guan, Juan Zhang, Xinrui Cai, Yanan Cai, Ziqiong Song, Yuan Huang, Weibin Qian, Zhifeng Pan, Xingguo Zhang. Astragaloside IV inhibits epithelial-mesenchymal transition and pulmonary fibrosis via lncRNA-ATB/miR-200c/ZEB1 signaling pathway. Gene. 2024 Mar; 897(?):148040. doi: 10.1016/j.gene.2023.148040. [PMID: 38065426]
  • Tiaohao Li, Xiaojuan Gao, Rui Jia, Yanling Sun, Yeli Ding, Fei Wang, Yujuan Wang. Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway. Cellular and molecular biology (Noisy-le-Grand, France). 2024 Feb; 70(2):128-136. doi: 10.14715/cmb/2024.70.2.18. [PMID: 38430031]
  • Yan-Ling Li, Zhan-Hui Lu, Yan-Yan Zhang, Sha-Sha Wu, Tian-Hao Xie, Huang Ding, Wei Zhang, Xiao-Dan Liu, Chang-Qing Deng. [Mechanism of astragaloside Ⅳ combined with Panax notoginseng saponins in regulating angiogenesis to treat cerebral ischemia based on network pharmacology and experimental verification]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2024 Feb; 49(4):1017-1027. doi: 10.19540/j.cnki.cjcmm.20230901.401. [PMID: 38621909]
  • Muzhe Li, Yuanyuan Niu, Linkun Tian, Tianchi Zhang, Shijie Zhou, Lining Wang, Jie Sun, Taxi Wumiti, Zhiwei Chen, Qinfeng Zhou, Yong Ma, Yang Guo. Astragaloside IV alleviates macrophage senescence and d-galactose-induced bone loss in mice through STING/NF-κB pathway. International immunopharmacology. 2024 Jan; 129(?):111588. doi: 10.1016/j.intimp.2024.111588. [PMID: 38290207]
  • Qing-Qing Yang, Hong-Ying Zhang, Xiao-Hong Duan, Mi-Hui Li, Jing Sun, Li-Xia Tian, Jing-Cheng Dong, Ling-Wen Kong. Astragaloside IV targeting autophagy of T cells improves inflammation of asthma. Journal of Asian natural products research. 2024 Jan; ?(?):1-15. doi: 10.1080/10286020.2023.2294069. [PMID: 38213072]
  • Xiaojie Liu, Senyan Wang, Xiaoling Wu, Ziyu Zhao, Chen Jian, Mengyu Li, Xuemei Qin. Astragaloside IV Alleviates Depression in Rats by Modulating Intestinal Microbiota, T-Immune Balance, and Metabolome. Journal of agricultural and food chemistry. 2024 Jan; 72(1):259-273. doi: 10.1021/acs.jafc.3c04063. [PMID: 38064688]
  • Jingge Xu, Zhiyu Zhang, Dongwen Ren, Luokun Liu, Haitao Xing, Dan Wang, Yuzheng Wu, Yi Zhang, Qian Chen, Tao Wang. Astragaloside Ⅳ negatively regulates Gpr97-TPL2 signaling to protect against hyperhomocysteine-exacerbated sepsis associated acute kidney injury. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024 Jan; 125(?):155346. doi: 10.1016/j.phymed.2024.155346. [PMID: 38237511]
  • Yanghao Li, Xu Yang, Tiantian Bao, Xiaojuan Sun, Xiang Li, Huilin Zhu, Bo Zhang, Tonghui Ma. Radix Astragali decoction improves liver regeneration by upregulating hepatic expression of aquaporin-9. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024 Jan; 122(?):155166. doi: 10.1016/j.phymed.2023.155166. [PMID: 37918281]
  • Pengfei Kong, Xuemei Tang, Fang Liu, Xuegui Tang. Astragaloside IV regulates circ_0001615 and miR-873-5p/LASP1 axis to suppress colorectal cancer cell progression. Chemical biology & drug design. 2024 Jan; 103(1):e14423. doi: 10.1111/cbdd.14423. [PMID: 38230773]
  • Xu-Jun You, Zheng Wen, Qing-Xia Zheng, Qi-Xin Li, Wei Fu, Hai-Song Li, Bin Wang. [Explore the mechanism of astragaloside IV-PESV on proliferation, migration, and autophagy of prostate cancer cells based on the PI3K/AKT signaling pathway]. Zhonghua nan ke xue = National journal of andrology. 2023 Dec; 29(12):963-972. doi: ". [PMID: 38639947]
  • Shan Wu, Fei Wen, Xiangbin Zhong, Wenjing Du, Manlian Chen, Junyi Wang. Astragaloside IV ameliorate acute alcohol-induced liver injury in mice via modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway. Annals of medicine. 2023 Dec; 55(1):2216942. doi: 10.1080/07853890.2023.2216942. [PMID: 37243569]
  • Xiulian Zhang, Xueliang Li, Wei Ma, Fangying Liu, Pinxian Huang, Lei Wei, Li Li, Yechang Qian. Astragaloside IV restores Th17/Treg balance via inhibiting CXCR4 to improve chronic obstructive pulmonary disease. Immunopharmacology and immunotoxicology. 2023 Dec; 45(6):682-691. doi: 10.1080/08923973.2023.2228479. [PMID: 37417915]
  • Zehui Xu, Houle Zhou, Yihan Zhang, Ziji Cheng, Melisandre Wan, Wanting Qin, Peiyu Li, Jiaming Feng, Shuijin Shao, Wenlong Xue, Haidong Guo, Baonian Liu. Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Dec; 168(?):115752. doi: 10.1016/j.biopha.2023.115752. [PMID: 37875045]
  • Lin Zhou, Xiaohui Wang, Jinlan Xia, Liyuan Zhang, Lianping Xue, Qingquan Jia, Zhihui Fu, Zhi Sun. Pharmacokinetic-pharmacodynamic modeling of the active components of Shenkang injection in rats with chronic renal failure and its protective effect on damaged renal cells. Biopharmaceutics & drug disposition. 2023 Dec; 44(6):406-419. doi: 10.1002/bdd.2377. [PMID: 37679901]
  • Wu Xiong, Xue Bai, Xi Zhang, Huajuan Lei, Hui Xiao, Luyao Zhang, Yuting Xiao, Qianpei Yang, Xiaoling Zou. Endothelial Progenitor-Cell-Derived Exosomes Induced by Astragaloside IV Accelerate Type I Diabetic-wound Healing via the PI3K/AKT/mTOR Pathway in Rats. Frontiers in bioscience (Landmark edition). 2023 Nov; 28(11):282. doi: 10.31083/j.fbl2811282. [PMID: 38062822]
  • Yue Shi, Xiujie Shi, Mingming Zhao, Sijia Ma, Yu Zhang. Pharmacological potential of Astragali Radix for the treatment of kidney diseases. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2023 Nov; 123(?):155196. doi: 10.1016/j.phymed.2023.155196. [PMID: 37952410]
  • Bing Zhang, Shiying Huang, Zhuoting Liu, Xinhui Liu, Zilan Jiang, Jianping Chen, Youjia Zeng. Investigation of the Metabolism of Astragaloside IV in a Puromycin-Damaged Rat Model by UPLC-Q-TOF-MS/MS Analysis. Planta medica. 2023 Nov; ?(?):. doi: 10.1055/a-2186-3182. [PMID: 37931776]
  • Man Zhang, Wenshuang Wang, Kaixin Liu, Chao Jia, Yuanyuan Hou, Gang Bai. Astragaloside IV protects against lung injury and pulmonary fibrosis in COPD by targeting GTP-GDP domain of RAS and downregulating the RAS/RAF/FoxO signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2023 Nov; 120(?):155066. doi: 10.1016/j.phymed.2023.155066. [PMID: 37690229]
  • Haihao Yang, Na Yin, Qianlan Gu, Zhao Wu, Ying Xu, Jie Gao, Dongdong Qin, Chunping Wan. Astragaloside IV reduces lung injury in lethal sepsis via promoting treg cells expansion and inhibiting inflammatory responses. Pakistan journal of pharmaceutical sciences. 2023 Nov; 36(6):1709-1718. doi: . [PMID: 38124410]
  • Milton Packer. Qiliqiangxin: A multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms?. European journal of heart failure. 2023 Oct; ?(?):. doi: 10.1002/ejhf.3068. [PMID: 37877337]
  • Hong Wang, Liangyin Wei, Dengxuan Mao, Xiaoyu Che, Xietao Ye, Yuping Liu, Yan Chen. Combination of oxymatrine (Om) and astragaloside IV (As) enhances the infiltration and function of TILs in triple-negative breast cancer (TNBC). International immunopharmacology. 2023 Oct; 125(Pt A):111026. doi: 10.1016/j.intimp.2023.111026. [PMID: 37866315]
  • Jingjing Wan, Zhen Zhang, Chennan Wu, Saisai Tian, Yibei Zang, Ge Jin, Qingyan Sun, Pin Wang, Xin Luan, Yili Yang, Xuelin Zhan, Lingyu Linda Ye, Dayue Darrel Duan, Xia Liu, Weidong Zhang. Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456. Signal transduction and targeted therapy. 2023 10; 8(1):414. doi: 10.1038/s41392-023-01660-9. [PMID: 37857609]
  • Jie Xi, Yan Ma, Dongmei Liu, Rong Li. Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway. BMC pulmonary medicine. 2023 Oct; 23(1):386. doi: 10.1186/s12890-023-02660-9. [PMID: 37828459]
  • Tang Ziyang, Hu Xirong, An Chongming, Li Tingxin. The potential molecular pathways of Astragaloside-IV in colorectal cancer: A systematic review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Oct; 167(?):115625. doi: 10.1016/j.biopha.2023.115625. [PMID: 37793276]
  • Zemei Liu, Yuanju Lv, Guangyan Zheng, Wenli Wu, Xin Che. Chitosan/Polylactic Acid Nanofibers Containing Astragaloside IV as a New Biodegradable Wound Dressing for Wound Healing. AAPS PharmSciTech. 2023 Oct; 24(7):202. doi: 10.1208/s12249-023-02650-4. [PMID: 37783916]
  • Jia-Xin Long, Meng-Zhi Tian, Xiao-Yi Chen, Yu Xiong, Huang-He Yu, Yong-Zhen Gong, Huang Ding, Ming-Xia Xie, Ke DU. [Mechanism of astragaloside Ⅳ in regulating autophagy of PC12 cells under oxygen-glucose deprivation by medicating Akt/mTOR/HIF-1α pathway]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2023 Oct; 48(19):5271-5277. doi: 10.19540/j.cnki.cjcmm.20230630.402. [PMID: 38114116]
  • Xiao Zhao, Lixue Sun, Jing Wang, Xiaolu Xu, Shuting Ni, Mei Liu, Kaili Hu. Nose to brain delivery of Astragaloside IV by β-Asarone modified chitosan nanoparticles for multiple sclerosis therapy. International journal of pharmaceutics. 2023 Sep; 644(?):123351. doi: 10.1016/j.ijpharm.2023.123351. [PMID: 37640088]
  • Wu Xiong, Xi Zhang, Jianda Zhou, Jie Chen, Yu Liu, Yu Yan, Meixin Tan, Hongyu Huang, Yuqi Si, Yang Wei. Astragaloside IV promotes exosome secretion of endothelial progenitor cells to regulate PI3KR2/SPRED1 signaling and inhibit pyroptosis of diabetic endothelial cells. Cytotherapy. 2023 Sep; ?(?):. doi: 10.1016/j.jcyt.2023.08.013. [PMID: 37747393]
  • Zhilin Li, En Hu, Fei Zheng, Song Wang, Wei Zhang, Jiekun Luo, Tao Tang, Qing Huang, Yang Wang. The effects of astragaloside IV on gut microbiota and serum metabolism in a mice model of intracerebral hemorrhage. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2023 Sep; 121(?):155086. doi: 10.1016/j.phymed.2023.155086. [PMID: 37783132]
  • Ning Liu, Yansu Ji, Rui Liu, Xin Jin. The state of astragaloside IV research: A bibliometric and visualized analysis. Fundamental & clinical pharmacology. 2023 Sep; ?(?):e12956. doi: 10.1111/fcp.12956. [PMID: 37700611]
  • Jianwei Ren, Yuetian Ding, Shangze Li, Ming Lei. Predicting the anti-inflammatory mechanism of Radix Astragali using network pharmacology and molecular docking. Medicine. 2023 Sep; 102(35):e34945. doi: 10.1097/md.0000000000034945. [PMID: 37657026]
  • Yunlong Chen, Mianhua Wu. Exploration of molecular mechanism underlying protective effect of astragaloside IV against radiation-induced lung injury by suppressing ferroptosis. Archives of biochemistry and biophysics. 2023 09; 745(?):109717. doi: 10.1016/j.abb.2023.109717. [PMID: 37573925]
  • Yutong Liang, Biqiong Chen, Di Liang, Xiaoxiao Quan, Ruolan Gu, Zhiyun Meng, Hui Gan, Zhuona Wu, Yunbo Sun, Shuchen Liu, Guifang Dou. Pharmacological Effects of Astragaloside IV: A Review. Molecules (Basel, Switzerland). 2023 Aug; 28(16):. doi: 10.3390/molecules28166118. [PMID: 37630371]
  • Mingxia Xie, Bohou Xia, Lan Xiao, Dun Yang, Zhenghong Li, Hanqing Wang, Xiaoye Wang, Xi Zhang, Qinghua Peng. Astragaloside IV ameliorates peritoneal fibrosis by promoting PGC-1α to reduce apoptosis in vitro and in vivo. Journal of cellular and molecular medicine. 2023 Jul; ?(?):. doi: 10.1111/jcmm.17871. [PMID: 37494130]
  • Dong Li, Yuzhe Liu, Quancao Zhan, Yan Zeng, Ze Peng, Qifeng He, Qi Tan, Wenfu Cao, Shang Wang, Jianwei Wang. Astragaloside IV Blunts Epithelial-Mesenchymal Transition and G2/M Arrest to Alleviate Renal Fibrosis via Regulating ALDH2-Mediated Autophagy. Cells. 2023 Jul; 12(13):. doi: 10.3390/cells12131777. [PMID: 37443810]
  • Zhenglong Jin, Wenying Gao, Fu Guo, Shaojun Liao, Mingzhe Hu, Tao Yu, Shangzhen Yu, Qing Shi. Astragaloside IV alleviates neuronal ferroptosis in ischemic stroke by regulating fat mass and obesity-associated-N6-methyladenosine-acyl-CoA synthetase long-chain family member 4 axis. Journal of neurochemistry. 2023 Jun; ?(?):. doi: 10.1111/jnc.15871. [PMID: 37300304]
  • Xin Liu, Yanping Ding, Chenxin Jiang, Xin Ma, Yuanyuan Xin, Yingdong Li, Shengxiang Zhang, Baoping Shao. Astragaloside IV ameliorates radiation-induced nerve cell damage by activating the BDNF/TrkB signaling pathway. Phytotherapy research : PTR. 2023 May; ?(?):. doi: 10.1002/ptr.7872. [PMID: 37226643]
  • Katarzyna Stępnik, Wirginia Kukula-Koch, Wojciech Plazinski, Kinga Gawel, Katarzyna Gaweł-Bęben, Daariimaa Khurelbat, Anna Boguszewska-Czubara. Significance of Astragaloside IV from the Roots of Astragalus mongholicus as an Acetylcholinesterase Inhibitor-From the Computational and Biomimetic Analyses to the In Vitro and In Vivo Studies of Safety. International journal of molecular sciences. 2023 May; 24(11):. doi: 10.3390/ijms24119152. [PMID: 37298103]
  • Yenan Mo, Dongmei Hu, Wanlin Yu, Chunlan Ji, Yin Li, Xusheng Liu, Zhaoyu Lu. Astragaloside IV attenuates indoxyl sulfate-induced injury of renal tubular epithelial cells by inhibiting the aryl hydrocarbon receptor pathway. Journal of ethnopharmacology. 2023 May; 308(?):116244. doi: 10.1016/j.jep.2023.116244. [PMID: 36764562]
  • Xue Su, Hengjiang Guo, Yuying Zhou, Aili Cao, Qian Shen, Bingbing Zhu, Xingmei Yao, Yunman Wang, Hao Wang, Li Wang. Astragaloside IV attenuates high glucose-induced NF-κB-mediated inflammation through activation of PI3K/AKT-ERK-dependent Nrf2/ARE signaling pathway in glomerular mesangial cells. Phytotherapy research : PTR. 2023 May; ?(?):. doi: 10.1002/ptr.7875. [PMID: 37189016]
  • Cai-Yun Chen, Run Zhang, Li-Jie Zhang, Zhi-Yong Hu, Shao-Ping Wang, Xue Mei, Wei Mi, Jia-Yu Zhang. Biotransformation and bioaccessibility of active ingredients from Radix Astragali by Poria cocos during solid-state fermentation and in vitro digestion and antioxidant activity evaluation. Scientific reports. 2023 Apr; 13(1):6888. doi: 10.1038/s41598-023-33969-4. [PMID: 37106016]
  • Huang Ding, Xiao-Ping Huang, Xiao-Dan Liu, Yan-Ling Li, San Tang, Hai-Long Xiong, Mei-Ting Huang, Ying Li, Cai-Xia Liu, Wei Zhang, Chang-Qing Deng. Effects of borneol combined with astragaloside IV and Panax notoginseng saponins regulation of microglia polarization to promote neurogenesis after cerebral ischaemia. The Journal of pharmacy and pharmacology. 2023 Apr; ?(?):. doi: 10.1093/jpp/rgad033. [PMID: 37185938]
  • Rui-Hua Zhang, Shan-Shan Cao, Yong Shi, Xin Wang, Lei-Lei Shi, Yu-Han Zhang, Chao-Jun Han, Bin Wang, Liang Feng, Ji-Ping Liu. Astragaloside IV-mediated inhibition of oxidative stress by upregulation of ghrelin in type 2 diabetes-induced cognitive impairment. Naunyn-Schmiedeberg's archives of pharmacology. 2023 Apr; ?(?):. doi: 10.1007/s00210-023-02486-6. [PMID: 37097336]
  • Jiaxiong Yao, Junqiu Liu, Yining He, Lin Liu, Zonghui Xu, Xianming Lin, Na Liu, Guoyin Kai. Systems pharmacology reveals the mechanism of Astragaloside IV in improving immune activity on cyclophosphamide-induced immunosuppressed mice. Journal of ethnopharmacology. 2023 Apr; 313(?):116533. doi: 10.1016/j.jep.2023.116533. [PMID: 37100262]
  • Qian Shen, Ji Fang, Hengjiang Guo, Xue Su, Bingbing Zhu, Xingmei Yao, Yunman Wang, Aili Cao, Hao Wang, Li Wang. Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease. Free radical biology & medicine. 2023 Apr; ?(?):. doi: 10.1016/j.freeradbiomed.2023.03.022. [PMID: 37030337]
  • Fan Xu, Minghua Li, Zujun Que, Mingliang Su, Wang Yao, Yu Zhang, Bin Luo, Yan Li, Zhanxia Zhang, Jianhui Tian. Combined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancer. Journal of materials chemistry. B. 2023 Apr; ?(?):. doi: 10.1039/d2tb02328h. [PMID: 37009696]
  • Chuanjing Cheng, Kaixin Liu, Fukui Shen, Jinling Zhang, Yang Xie, Suyun Li, Yuanyuan Hou, Gang Bai. Astragaloside IV targets PRDX6, inhibits the activation of RAC subunit in NADPH oxidase 2 for oxidative damage. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2023 Mar; 114(?):154795. doi: 10.1016/j.phymed.2023.154795. [PMID: 37030053]
  • Zhineng Kang, Qian Xiao, Linlin Wang, Lan Xiao, Biao Tang. The combination of astragaloside IV and Panax notoginseng saponins attenuates cerebral ischaemia-reperfusion injury in rats through ferroptosis and inflammation inhibition via activating Nrf2. The Journal of pharmacy and pharmacology. 2023 Mar; ?(?):. doi: 10.1093/jpp/rgad011. [PMID: 36952592]
  • Xin Li, Ziwei Li, Xin Dong, Yu Wu, Baohua Li, Bin Kuang, Gangyi Chen, Liangyou Zhang. Astragaloside IV attenuates myocardial dysfunction in diabetic cardiomyopathy rats through downregulation of CD36-mediated ferroptosis. Phytotherapy research : PTR. 2023 Mar; ?(?):. doi: 10.1002/ptr.7798. [PMID: 36882189]
  • Linwei Chen, Nina Wei, Yong Jiang, Chengye Yuan, Luwei Xu, Jindong Li, Min Kong, Yan Chen, Qin Wang. Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS. Journal of ethnopharmacology. 2023 Mar; 303(?):116035. doi: 10.1016/j.jep.2022.116035. [PMID: 36513265]
  • Min Yao, Lijuan Zhang, Lin Wang. Astragaloside IV: A promising natural neuroprotective agent for neurological disorders. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Mar; 159(?):114229. doi: 10.1016/j.biopha.2023.114229. [PMID: 36652731]
  • Ying-Ying Li, Zeng-Hui Tian, Shan-Shan Su, Jing-Jing Shi, Chao Zhou, Li-Hua Zhang, Fa-Rong Zhang, Yan-Ke Hao. Anti-apoptotic effect of HeidihuangWan in renal tubular epithelial cells via PI3K/Akt/mTOR signaling pathway. Journal of ethnopharmacology. 2023 Feb; 302(Pt A):115882. doi: 10.1016/j.jep.2022.115882. [PMID: 36341817]
  • Lele Wang, Canwen Liu, Linlin Wang, Biao Tang. Astragaloside IV mitigates cerebral ischaemia-reperfusion injury via inhibition of P62/Keap1/Nrf2 pathway-mediated ferroptosis. European journal of pharmacology. 2023 Feb; 944(?):175516. doi: 10.1016/j.ejphar.2023.175516. [PMID: 36758783]
  • Ding Yanping, Dong Xiaoqing, M A Yifan, Chen Lili, Zhou Jie, L I Xinyan, Shao Baoping. Astragaloside IV plays a role in reducing radiation-induced liver inflammation in mice by inhibiting thioredoxin-interacting protein/nod-like receptor protein 3 signaling pathway. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan. 2023 02; 43(1):87-94. doi: 10.19852/j.cnki.jtcm.2023.01.008. [PMID: 36639999]
  • Xia Li, Hong Guo, Deng-Xuan Mao, Yu-Ping Liu, Yan Chen. [Preparation of two tanshinone Ⅱ_A-astragaloside Ⅳ co-loaded nano-delivery systems and in vitro antitumor activity comparison]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2023 Feb; 48(3):672-680. doi: 10.19540/j.cnki.cjcmm.20221127.302. [PMID: 36872230]
  • Liping Cao, Jinliang Du, Rui Jia, Jiancao Gao, Zhijuan Nie, Nailin Shao, Quanjie Li, Haojun Zhu, Guojun Yin, Weidong Ding, Gangchun Xu. Alleviative effects of astragaloside IV on cyclophosphamide-induced oxidative damage and immunosuppression in tilapia (Oreochromis niloticus). Comparative biochemistry and physiology. Toxicology & pharmacology : CBP. 2023 Feb; 264(?):109503. doi: 10.1016/j.cbpc.2022.109503. [PMID: 36368505]
  • Y E Xiaomei, Xing Xiaowei, Yuan Kangrui, Wang Dongming, W U Dudu, Chen Zhi, Y U Zhiqiang. Astragaloside IV ameliorates insulin induced insulin resistance in HepG2 cells through reactive oxygen species mediated c-Jun N-terminal kinase pathway. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan. 2023 02; 43(1):60-67. doi: 10.19852/j.cnki.jtcm.2023.01.007. [PMID: 36639996]
  • Fanchen Yan, Huang Ding, Zhengji Sun, Jingze Liu, Junxi Li, Dan Zhou, Wei Zhang. Glycoside combinations of Buyang Huanwu decoction ameliorate atherosclerosis via STAT3, HIF-1, and VEGF. Naunyn-Schmiedeberg's archives of pharmacology. 2023 Jan; ?(?):. doi: 10.1007/s00210-023-02389-6. [PMID: 36692827]
  • Wu Xiong, Jian-da Zhou, Mei-Xin Tan, Yu Liu, Yu Yan, Hua-Juan Lei, Jia-Rui Peng, Wei Liu, Pei Tan, Xi Zhang. Astragaloside IV (ASIV) Mediates Endothelial Progenitor Cell (EPC) Exosomal LINC01963 to Inhibit Pyroptosis and Oxidative Stress in High Glucose-impaired Endothelial Cells. Current molecular medicine. 2023 Jan; ?(?):. doi: 10.2174/1566524023666230111163718. [PMID: 36631922]
  • Liangxing Zhou, Mengpeng Li, Zhengbin Chai, Junli Zhang, Kuan Cao, Lei Deng, Yanming Liu, Cun Jiao, Gang-Ming Zou, Jibiao Wu, Fabin Han. Anticancer effects and mechanisms of astragaloside‑IV (Review). Oncology reports. 2023 01; 49(1):. doi: 10.3892/or.2022.8442. [PMID: 36367181]
  • Lei Li, Jie Guan, Rongjun Lin, Fang Wang, Hui Ma, Chenggang Mao, Xingqing Guo, Zhenghai Qu, Renzheng Guan. Astragaloside IV alleviates lung inflammation in Klebsiella pneumonia rats by suppressing TGF-β1/Smad pathway. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2023; 56(?):e12203. doi: 10.1590/1414-431x2023e12203. [PMID: 37493767]
  • Jiaxin He, Jialin Cui, Yimin Shi, Tao Wang, Junyan Xin, Yimeng Li, Xiaomeng Shan, Zhiyao Zhu, Yanbin Gao. Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis. Journal of diabetes research. 2023; 2023(?):7423661. doi: 10.1155/2023/7423661. [PMID: 37261217]
  • Xuxi Guo, Taoqing Yin, Dongni Chen, Shuai Xu, Renqun Ye, Yue Zhang. Astragaloside IV Regulates Insulin Resistance and Inflammatory Response of Adipocytes via Modulating MIR-21/PTEN/PI3K/AKT Signaling. Endocrine, metabolic & immune disorders drug targets. 2023; 23(12):1538-1547. doi: 10.2174/1871530323666230627121700. [PMID: 37366351]
  • Lin Li, Yuwei Zhang, Yudan Luo, Xianghui Meng, Guixiang Pan, Han Zhang, Yuhong Li, Boli Zhang. The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications. Drug design, development and therapy. 2023; 17(?):771-790. doi: 10.2147/dddt.s399423. [PMID: 36925998]
  • Fengyan Shen, Yong Meng, Yuhai He, Bowan Huang, Jinxin Huang, Lu Wang. Antihypertension effect of astragaloside IV during cerebral ischemia reperfusion in rats. Molecular medicine reports. 2023 01; 27(1):. doi: 10.3892/mmr.2022.12890. [PMID: 36331022]
  • Kuangyang Yang, Qian Xie, Tingting Tang, Na Zhao, Jianhui Liang, Yanni Shen, Ziqi Li, Ben Liu, Jianhai Chen, Wenxiang Cheng, Xueling Bai, Peng Zhang, Qian Liu, Bing Song, Chun Hu, Lichu Liu, Yan Wang. Astragaloside IV as a novel CXCR4 antagonist alleviates osteoarthritis in the knee of monosodium iodoacetate-induced rats. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2023 Jan; 108(?):154506. doi: 10.1016/j.phymed.2022.154506. [PMID: 36403512]
  • Jingwen Yu, Bingtao Mu, Minfang Guo, Chunyun Liu, Tao Meng, Yuqing Yan, Lijuan Song, Jiezhong Yu, Gajendra Kumar, Cungen Ma. Astragaloside IV inhibits experimental autoimmune encephalomyelitis by modulating the polarization of both microglia/macrophages and astrocytes. Folia neuropathologica. 2023; 61(3):273-290. doi: 10.5114/fn.2023.129066. [PMID: 37818688]
  • Chunlei Zhang, Zhonghua Shi, Qinyi Xu, Jianqing He, Lei Chen, Zehua Lu, Qiaohua Huan, Yuhai Wang, Gang Cui. Astragaloside IV alleviates stroke-triggered early brain injury by modulating neuroinflammation and ferroptosis via the Nrf2/HO-1 signaling pathway. Acta cirurgica brasileira. 2023; 38(?):e380723. doi: 10.1590/acb380723. [PMID: 36995819]
  • Su Yuan, Biao Zuo, Si-Cong Zhou, Meng Wang, Kai-Yue Tan, Zhi-Wei Chen, Wen-Fu Cao. Integrating Network Pharmacology and Experimental Validation to Explore the Pharmacological Mechanism of Astragaloside IV in Treating Bleomycin-Induced Pulmonary Fibrosis. Drug design, development and therapy. 2023; 17(?):1289-1302. doi: 10.2147/dddt.s404710. [PMID: 37138582]
  • Yueyang Tian, Xu Chu, Qia Huang, Xing Guo, Yuan Xue, Weimin Deng. Astragaloside IV attenuates IL-1β-induced intervertebral disc degeneration through inhibition of the NF-κB pathway. Journal of orthopaedic surgery and research. 2022 Dec; 17(1):545. doi: 10.1186/s13018-022-03438-1. [PMID: 36527065]
  • Yi Su, Xin Yin, Xin Huang, Qianqian Guo, Mingyuan Ma, Liheng Guo. Astragaloside IV ameliorates sepsis-induced myocardial dysfunction by regulating NOX4/JNK/BAX pathway. Life sciences. 2022 Dec; 310(?):121123. doi: 10.1016/j.lfs.2022.121123. [PMID: 36302499]
  • Shencun Yu, Wendong Peng, Fanghong Qiu, Guiju Zhang. Research progress of astragaloside IV in the treatment of atopic diseases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Dec; 156(?):113989. doi: 10.1016/j.biopha.2022.113989. [PMID: 36411656]
  • Sen Sun, Lu Liu, Hongming Song, Hong Li. Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats. Pharmaceutical biology. 2022 Dec; 60(1):1944-1948. doi: 10.1080/13880209.2022.2125539. [PMID: 36226863]
  • Yi Su, Xin Yin, Xin Huang, Qianqian Guo, Mingyuan Ma, Liheng Guo. The BCL2/BAX/ROS pathway is involved in the inhibitory effect of astragaloside IV on pyroptosis in human umbilical vein endothelial cells. Pharmaceutical biology. 2022 Dec; 60(1):1812-1818. doi: 10.1080/13880209.2022.2101668. [PMID: 36121248]
  • Jie Zhang, Yumei Yan, Fang Cheng, Feixiang Huang, Xingliang Xie, Yanmei Sheng. Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells. Journal of visualized experiments : JoVE. 2022 11; ?(189):. doi: 10.3791/64721. [PMID: 36468713]
  • Jingwen Yu, Minfang Guo, Pengwei Yang, Yanhua Li, Chunyun Liu, Lijuan Song, Zhi Chai, Jiezhong Yu, Cungen Ma. [Astragaloside IV inhibits oxidative stress-mediated apoptosis of human SY5Y cells by activating Nrf-2/HO-1 signaling pathway]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2022 Nov; 38(11):979-985. doi: . [PMID: 36328427]
  • Xiaoqing Zhang, Huiyan Qu, Tao Yang, Qian Liu, Hua Zhou. Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway. Cell cycle (Georgetown, Tex.). 2022 Nov; 21(21):2309-2322. doi: 10.1080/15384101.2022.2093598. [PMID: 35770948]
  • Xiaoming Wang, Yilan Wang, Demei Huang, Shihua Shi, Caixia Pei, Yongcan Wu, Zherui Shen, Fei Wang, Zhenxing Wang. Astragaloside IV regulates the ferroptosis signaling pathway via the Nrf2/SLC7A11/GPX4 axis to inhibit PM2.5-mediated lung injury in mice. International immunopharmacology. 2022 Nov; 112(?):109186. doi: 10.1016/j.intimp.2022.109186. [PMID: 36115280]
  • Yu Du, Chang Li, Shouchao Xu, Jiehong Yang, Haitong Wan, Yu He. LC-MS/MS combined with blood-brain dual channel microdialysis for simultaneous determination of active components of astragali radix-safflower combination and neurotransmitters in rats with cerebral ischemia reperfusion injury: Application in pharmacokinetic and pharmacodynamic study. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2022 Nov; 106(?):154432. doi: 10.1016/j.phymed.2022.154432. [PMID: 36113188]
  • Yixian Lin, Hui Zhang, Peirong Li, Juan Jin, Zhefei Li. The bacterial consortia promote plant growth and secondary metabolite accumulation in Astragalus mongholicus under drought stress. BMC plant biology. 2022 Oct; 22(1):475. doi: 10.1186/s12870-022-03859-4. [PMID: 36203134]
  • Susan M Britza, Ian F Musgrave, Roger W Byard. Implications for herbal polypharmacy: coumarin-induced hepatotoxicity increased through common herbal phytochemicals astragaloside IV and atractylenolide I. Toxicology mechanisms and methods. 2022 Oct; 32(8):606-615. doi: 10.1080/15376516.2022.2057267. [PMID: 35354423]
  • Youbao Zhong, Wenjun Liu, Yanxia Xiong, Yingmeng Li, Qi Wan, Wen Zhou, Haimei Zhao, Qiuping Xiao, Duanyong Liu. Astragaloside Ⅳ alleviates ulcerative colitis by regulating the balance of Th17/Treg cells. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2022 Sep; 104(?):154287. doi: 10.1016/j.phymed.2022.154287. [PMID: 35752072]
  • Yonghong Lian, Cuiqiong Li, Jianchun Li, Yongxiang Xie, Qiancheng Liu, Minhua Wu, Wei Shi, Lifeng Meng. Astragaloside IV attenuated TGF-β1- induced epithelial-mesenchymal transition of renal tubular epithelial cells via connexin 43 and Akt/mTOR signaling pathway. Tissue & cell. 2022 Aug; 77(?):101831. doi: 10.1016/j.tice.2022.101831. [PMID: 35643056]
  • Yin Xiuping, Zhang Xiaotong, Zhu Rongjia, Song Ping. Effect of astragaloside IV on the immunoregulatory function of adipose-derived mesenchymal stem cells from patients with psoriasis vulgaris. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan. 2022 08; 42(4):513-519. doi: 10.19852/j.cnki.jtcm.20220516.002. [PMID: 35848967]
  • Xiang-Lin Kong, Qin Lyu, Ya-Qi Zhang, Dong-Fang Kang, Chao Li, Lei Zhang, Zi-Chen Gao, Xin-Xin Liu, Ji-Biao Wu, Yun-Lun Li. Effect of astragaloside IV and salvianolic acid B on antioxidant stress and vascular endothelial protection in the treatment of atherosclerosis based on metabonomics. Chinese journal of natural medicines. 2022 Aug; 20(8):601-613. doi: 10.1016/s1875-5364(22)60186-9. [PMID: 36031232]
  • Hui Wu, Gao-Rui Wang, Xin-Ting Wang, Yu-Yan Bai, Jin-Feng Yuan, Liu Yang, Fei Huang, Hai-Lian Shi, Xiao-Jun Wu. Astragaloside IV ameliorates metabolic disorder in db/db obese mice as a PPARγ antagonist. Journal of Asian natural products research. 2022 Jul; ?(?):1-13. doi: 10.1080/10286020.2022.2098726. [PMID: 35866240]
  • Jia-Long Tang, Meng Xin, Li-Chao Zhang. Protective effect of Astragalus membranaceus and Astragaloside IV in sepsis-induced acute kidney injury. Aging. 2022 Jul; 14(14):5855-5877. doi: 10.18632/aging.204189. [PMID: 35859295]
  • Yang-Yang Luo, Xuan Zhang, Fu-Sheng Zhang, Hui-Juan Li, Jian-Qin Zhang, Guan-Hua DU, Xue-Mei Qin. [Molecular mechanism underlying difference of astragaloside Ⅳ content in imitating wild and cultivated Astragalus mongholicus]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2022 Jul; 47(13):3463-3474. doi: 10.19540/j.cnki.cjcmm.20220416.103. [PMID: 35850797]
  • Wei Ning, Xiaogang Liao, Xingyou Dong, Yangcai Wang, Xingliang Yang, Jie Xu, Shanhong Yi, Zhenxing Yang. Protective effect of astragaloside IV on cadmium-induced spermatogenesis microenvironment damage in rats. Systems biology in reproductive medicine. 2022 Jun; 68(3):203-212. doi: 10.1080/19396368.2021.1983888. [PMID: 34711125]
  • Ke He, Li Yan, Se-Qi Lin, Yu-Ying Liu, Bai-He Hu, Xin Chang, Xin-Rong Zhao, Shu-Ya He, Xiao-Hong Wei, Jing-Yu Fan, Chun-Shui Pan, Jing-Yan Han. Implication of IGF1R signaling in the protective effect of Astragaloside IV on ischemia and reperfusion-induced cardiac microvascular endothelial hyperpermeability. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2022 Jun; 100(?):154045. doi: 10.1016/j.phymed.2022.154045. [PMID: 35338991]
  • Xili Xiao, Yanlin Zheng, Ya Mo, Wanjie Wang, Xiang Li, Juan Wang. Astragaloside IV alleviates oxidative stress-related damage via inhibiting NLRP3 inflammasome in a MAPK signaling dependent pathway in human lens epithelial cells. Drug development research. 2022 06; 83(4):1016-1023. doi: 10.1002/ddr.21929. [PMID: 35253245]